Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 21, 2025; 31(7): 101672
Published online Feb 21, 2025. doi: 10.3748/wjg.v31.i7.101672
CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma
Xue Yin, Na Deng, Xiao-Yan Ding, Jing-Long Chen, Wei Sun
Xue Yin, Na Deng, Xiao-Yan Ding, Jing-Long Chen, Wei Sun, Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Co-corresponding authors: Jing-Long Chen and Wei Sun.
Author contributions: Sun W and Chen JL designed the research study and acquired the funding, they contributed equally as co-corresponding authors; Yin X, Deng N, and Ding XY performed the research and contributed to data collection; Yin X contributed to data analysis, visualization, and manuscript preparation; and all authors have reviewed and agreed to the published version of the manuscript.
Supported by the Capital’s Funds for Health Improvement and Research, No. SF202222175.
Institutional review board statement: The study was reviewed and approved by the Institutional Ethics Committee of Beijing Ditan Hospital, Capital Medical University (approval No. KY2022014).
Informed consent statement: The requirement to obtain informed written consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The source data for this study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Sun, MD, Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. sunwei2134@163.com
Received: September 23, 2024
Revised: December 3, 2024
Accepted: December 30, 2024
Published online: February 21, 2025
Processing time: 118 Days and 23.4 Hours
Core Tip

Core Tip: The CRAFITY score, integrating baseline alpha-fetoprotein and C-reactive protein levels, has been limitedly investigated in patients receiving lenvatinib and programmed cell death protein 1 (PD-1) inhibitors. This study found significant differences in progression-free survival and overall survival across CRAFITY score strata in patients treated with lenvatinib and PD-1 inhibitors. Lower CRAFITY scores were associated with better objective response rates and disease control rates. These findings suggest that the CRAFITY score is a promising predictive tool for treatment response and survival in patients with unresectable hepatocellular carcinoma receiving lenvatinib and PD-1 inhibitors.